Xenon Pharmaceuticals Inc. Insider Trading

XENE

Last 12 months

Insiders bought $1.68M and sold $22M on the open market.

97% of the selling was scheduled in advance under 10b5-1 plans. Director Steven Gannon sold 641K on Aug 11, 84% of their stake, outside a plan.

Net open-market

−$20.3M

2 buys · 13 sales

Under a 10b5-1 plan

97%

of the value sold

Insiders who bought / sold

2 / 6

executives and directors

Last open-market buy

Sep 2026

Sep 30, 2026

Get an email when XENE's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 30	Thomas Patrick Kelly Chief Financial Officer	Bought	15,000	$37.32	560K	New	Form 4
Sep 30	Ian Mortimer President & CEO	Bought	30,000	$37.38	$1.12M	88%	Form 4
Aug 28	Christopher John Kenney Chief Medical Officer	Sold10b5-1 plan 2 parts	7,068	$60.25 average	426K	100%	Form 4
Aug 11	Steven Gannon Director	SoldNo plan	10,000	$64.06	641K	84%	Form 4
Jun 5	Gary Patou Director	Sold10b5-1 plan	1,322	$53.14	70K	4.2%	Form 4
Jun 5	Gillian Cannon Director	Sold10b5-1 plan	1,190	$53.14	63K	45%	Form 4
Mar 13	Christopher John Kenney Chief Medical Officer	Sold10b5-1 plan	1,410	$55.23	78K	17%	Form 4
Mar 13	Andrea Difabio Chief Legal Officer	Sold10b5-1 plan	1,342	$55.23	74K	16%	Form 4
Mar 13	Ian Mortimer President & CEO	Sold10b5-1 plan	7,308	$55.23	404K	18%	Form 4
Mar 10	Christopher John Kenney Chief Medical Officer	Sold10b5-1 plan	2,771	$60.11	167K	37%	Form 4
Mar 10	Andrea Difabio Chief Legal Officer	Sold10b5-1 plan	2,607	$60.11	157K	35%	Form 4
Mar 9 – 10	Ian Mortimer President & CEO	Sold10b5-1 plan 10 parts	281,269	$60.32 average	$17M	91%	Form 4
Jan 2	Ian Mortimer President & CEO	Sold10b5-1 plan 2 parts	40,000	$44.43 average	$1.78M	66%	Form 4
Dec 5, 2025 – Dec 8, 2025	Ian Mortimer President & CEO	Sold10b5-1 plan 3 parts	25,205	$45.33 average	$1.14M	55%	Form 4
Nov 28, 2025	Ian Mortimer President & CEO	Sold10b5-1 plan	97	$45.01	4K	0.2%	Form 4
Oct 1, 2025	Ian Mortimer President, CEO & Interim CFO	Sold10b5-1 plan	25,000	$40.16	$1M	35%	Form 4
Jun 5, 2025	Steven Gannon Director	SoldNo plan	3	$30.48	$91	<0.1%	Form 4
Jan 23, 2025 – Jan 27, 2025	Ian Mortimer President & CEO	Sold10b5-1 plan 4 parts	55,000	$40.25 average	$2.21M	55%	Form 4
Dec 18, 2024	Sherry Aulin Chief Financial Officer	SoldNo plan 2 parts	18,709	$41.21 average	771K	100%	Form 4
Nov 22, 2024	Gary Patou Director	SoldNo plan 2 parts	4,891	$41.08 average	201K	15%	Form 4

Sep 30
Thomas Patrick Kelly
Chief Financial Officer · bought 15,000 at $37.32
560K
New position
Sep 30
Ian Mortimer
President & CEO · bought 30,000 at $37.38
$1.12M
88% of stake
Aug 2810b5-1 plan
Christopher John Kenney
Chief Medical Officer · sold 7,068 at avg $60.25
426K
100% of stake
Aug 11No plan
Steven Gannon
Director · sold 10,000 at $64.06
641K
84% of stake
Jun 510b5-1 plan
Gary Patou
Director · sold 1,322 at $53.14
70K
4.2% of stake
Jun 510b5-1 plan
Gillian Cannon
Director · sold 1,190 at $53.14
63K
45% of stake
Mar 1310b5-1 plan
Christopher John Kenney
Chief Medical Officer · sold 1,410 at $55.23
78K
17% of stake
Mar 1310b5-1 plan
Andrea Difabio
Chief Legal Officer · sold 1,342 at $55.23
74K
16% of stake
Mar 1310b5-1 plan
Ian Mortimer
President & CEO · sold 7,308 at $55.23
404K
18% of stake
Mar 1010b5-1 plan
Christopher John Kenney
Chief Medical Officer · sold 2,771 at $60.11
167K
37% of stake
Mar 1010b5-1 plan
Andrea Difabio
Chief Legal Officer · sold 2,607 at $60.11
157K
35% of stake
Mar 9 – 1010b5-1 plan
Ian Mortimer
President & CEO · sold 281,269 at avg $60.32
$17M
91% of stake
Jan 210b5-1 plan
Ian Mortimer
President & CEO · sold 40,000 at avg $44.43
$1.78M
66% of stake
Dec 5, 2025 – Dec 8, 202510b5-1 plan
Ian Mortimer
President & CEO · sold 25,205 at avg $45.33
$1.14M
55% of stake
Nov 28, 202510b5-1 plan
Ian Mortimer
President & CEO · sold 97 at $45.01
4K
0.2% of stake
Oct 1, 202510b5-1 plan
Ian Mortimer
President, CEO & Interim CFO · sold 25,000 at $40.16
$1M
35% of stake
Jun 5, 2025No plan
Steven Gannon
Director · sold 3 at $30.48
$91
<0.1% of stake
Jan 23, 2025 – Jan 27, 202510b5-1 plan
Ian Mortimer
President & CEO · sold 55,000 at avg $40.25
$2.21M
55% of stake
Dec 18, 2024No plan
Sherry Aulin
Chief Financial Officer · sold 18,709 at avg $41.21
771K
100% of stake
Nov 22, 2024No plan
Gary Patou
Director · sold 4,891 at avg $41.08
201K
15% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch XENE, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with XENE

CompareIntrinsic value

ONCBeOne Medicines Ltd.

$370.04-0.41%65

ASMBAssembly Biosciences Inc.

$20.13-3.50%19

VRTXVertex Pharmaceuticals Incorporated

$558.88+3.50%47

HINDVyome Holdings, Inc

$1.80+2.86%20

CRVOCervoMed Inc.

$1.60-8.57%10

SCYXScynexis, Inc.

$3.72-3.63%40

CTMXCytomX Therapeutics Inc.

$2.34+2.18%10

IRWDIronwood Pharmaceuticals Inc.

$3.50-3.31%52

Held by ETFs

XENE is in 50 US ETFs. The largest of them, with XENE's weight in each:

Spot a number that looks wrong? Check it in XENE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing XENE

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.